Lv0
0 积分 2025-08-08 加入
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
8天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
15天前
已完结
Correspondence - Tranexamic acid for traumatic brain injury
15天前
已关闭
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1个月前
已完结
US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
1个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
3个月前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
4个月前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
10个月前
已完结
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
10个月前
已完结
皖公网安备34019202002308
